Previous 10 | Next 10 |
2023-03-25 10:44:38 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. For furthe...
2023-03-24 04:59:53 ET Summary All these stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 11.0% and a median increase of 8.4%. There are eighteen increases for next week to finish...
2023-03-21 06:30:00 ET Summary Markets are in turmoil. Volatility is high and the Fed is in a tough spot. In addition to discussing macroeconomic developments, I explain my strategy and thought process when it comes to buying quality dividend growth stocks. I highlight five di...
2023-03-20 08:57:38 ET Summary Dan Loeb's 13F portfolio value increased from $5.53B to $5.97B this quarter. The number of positions decreased from 61 to 44. Third Point added American International Group, Microsoft, and International Flavors & Fragrances while dropping Cano He...
2023-03-15 08:30:26 ET Summary In 2019 and 2020, Danaher Inc. issued mandatory convertible preferred stock. The former DHR.PA was converted in April 2022 and the latter DHR.PB is due for conversion in April 2023. DHR.PB offers an implied temporary dividend yield of 4.16% p.a. for ...
2023-03-15 07:02:07 ET Summary Agilent and Danaher have significantly outperformed the market, and have solid competitive advantages. The laboratory equipment and measurement devices industry is forecasted to grow at a ~7% CAGR to the year 2030. While we believe that both comp...
2023-03-14 06:00:00 ET Summary Markets are in turmoil. Hence, in this article, we start with a discussion of the risks facing investors and why I believe in attractive buying opportunities this year. While I understand that investors often opt for higher-yielding investments, I wi...
2023-03-09 08:34:12 ET Following the earnings season, Citi has taken a fresh look at its life science tools & diagnostics coverage, upgrading the colorectal cancer test maker Exact Sciences ( NASDAQ: EXAS ) and downgrading its rival Guardant Health ( NASDAQ: GH ). ...
2023-03-07 10:45:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Danaher Partners with the University of Pennsylvania's Center for Cellular Immunotherapies to Address Manufacturing Challenges Impacting the Uptake of Cell Therapies PR Newswire WASHINGTON , March 7, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 10:45:04 ET Pacific Biosciences of California Inc (PACB) PACB is trading UP for the last 5 days, and it at trading at $2.10 with volume of 3,952,245 and a one day change of $0.19 (9.97%). Pacific Biosciences of California Inc has a 52-week low of 1.16 and a 52-week high o...
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration PR Newswire BREA, Calif. , July 25, 2024 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the Dx...
2024-07-23 20:30:03 ET Goldman Sachs analyst issues NEUTRAL recommendation for DHR on July 23, 2024 06:19PM ET. The previous analyst recommendation was Neutral. DHR was trading at $264.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...